ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Cellyan Biotechnology Co. (HKPD)
Cellyan Biotechnology Co. stock price today, ATLAS forecast and fair value
Healthcare · Medical Distribution · NASDAQ
$2.14▼ -2.28%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
38%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Cellyan Biotechnology Co. in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Cellyan Biotechnology Co.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Cellyan Biotechnology Co. a 38% chance of finishing higher a month from now (21 trading sessions) than today: somewhat worse than a coin flip.
In half of the simulated outcomes the price ends between $1.35 and $2.57; in 9 out of 10, between $0.76 and $4.55. Estimated annual volatility is 200%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $5.4M
- 52-week high
- $30.60
- 52-week low
- $1.63
- Revenue (12 months)
- $13.4M
- Revenue growth (YoY)
- -33.9%
- Gross margin
- 10.3%
- Operating margin
- -7.5%
- Net margin
- -8.5%
- Return on equity
- -15.6%
- Free cash flow (12 months)
- $-6.5M
- Beta
- 0.00
What this means
ATLAS does not publish a fair value for HKPD right now, but it does show its odds of rising: somewhat worse than a coin flip.
Over the last 52 weeks HKPD has traded between $1.63 and $30.60. Today it is 93.0% below that high and 31% above its low.
On the business: revenue fell 33.9% year over year; net margin is 8.5%.
Its beta is 0.00: it tends to move less than the market.
About the company
Cellyan Biotechnology Co., Ltd is a Hong Kong-based biotechnology and pharmaceutical services company focused on over-the-counter pharmaceutical cross-border commerce.
Want to see everything about Cellyan Biotechnology Co.?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Cellyan Biotechnology Co. do?
Cellyan Biotechnology Co., Ltd is a Hong Kong-based biotechnology and pharmaceutical services company focused on over-the-counter pharmaceutical cross-border commerce.
What is the chance HKPD goes up next month?
38%: somewhat worse than a coin flip. In half of the simulated outcomes, HKPD ends the month between $1.35 and $2.57.
How big is Cellyan Biotechnology Co. and what is its P/E ratio?
Cellyan Biotechnology Co.'s market capitalization is $5.4M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is HKPD?
ATLAS estimates annual volatility at 200%. In a typical month, half of the outcomes end between $1.35 and $2.57.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer